Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

News

Exact Sciences' logo and The Oxford Science Park's logo. The Oxford Science Park's Sherard building is in the background.

Exact Sciences Innovation graduates to The Oxford Science Park

Helping people get the answers they need to make more informed decisions across the cancer continuum.

Cyanocapture logo

Introducing CyanoCapture

CyanoCapture aims for scalable, low-cost, biological carbon capture using genetically-modified algae, known as cyanobacteria.

Gene Linked to Doubling the Risk of Death due to COVID-19 Identified Using Technology Exclusively Licensed to Nucleome Therapeutics

The technology used to identify this gene has been exclusively licensed to Nucleome, highlighting the competitive advantage of Nucleome’s platform in the discovery of genetic targets for innovative precision medicine development.

The top half of the image is the Exogene logo on a pastel rainbow background. The lower half of the image is the KQ Labs logo and the Frances Crick Institute logo on a black background.

Exogene selected for KQ Labs accelerator programme

Exogene has been selected as one of ten innovative startup companies, working at the interface of biomedical and data science, to receive personalised mentoring and coaching as part of the KQ Labs accelerator programme.

Kyttaro logo

Introducing Kyttaro

Kyttaro is developing innovative therapeutics to treat hypertriglyceridemia, atherosclerotic cardiovascular disease and inflammatory and neurogastroenterology conditions.

Ochre Bio shortlisted as an OBN Awards 2021 finalist in the BioSeed ‘One to Watch’ Category

Recipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.

BioEscalator's 3rd anniversary

Oxford BioEscalator celebrates three years of innovation

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.

A row of bags of money, growing in size from left to right. The bags have plants growing out of them, also growing in size from left to right.

BioEscalator companies attract record funding as investors switch-on to biotech

Despite the disruption caused by the pandemic, BioEscalator companies attracted a record high of £1.2B investment. This is part of a trend that saw investors attracted to the resilience displayed by the life science industry to the pandemic relative to other sectors.

Coins are scattered and stacked behind a graph trending upwards. The PepGen logo is in the top left-hand corner of the image.

PepGen announces closing of $112.5M crossover financing to advance transformative therapies for neuromuscular diseases

Proceeds to support expansion and advancement of PepGen’s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases.

Theolytics logo

Theolytics graduates from the BioEscalator

After a highly successful start, Theolytics is ready for the next step in its journey and is moving to The Oxford Science Park. The company will be the first tenant moving into the newly refurbished Sherard Building.

OSPT logo

Introducing Oxford Silk Phage Technologies

Oxford Silk Phage Technologies combines the long-term expertise of clinicians, entrepreneurs and scientists with a shared passion for developing superior, natural antibacterial biomaterials to help people live more active and longer lives.

A DNA strand with a lightbulb at the top. OUBT Biohackathon 2021 winner. Evolvere Bioscience logo.

Evolvere Biosciences joins the BioEscalator community after winning the OUBT Biohackathon 2021

Evolvere joins our community for three months after winning the OUBT Biohacakthon 2021 BioEscalator sponsored prize.

The Medimab logo and the University Hospitals Birmingham logo are side by side on a grey background. Underneath is an image of scattered white dots connected with white lines on a navy blue background.

MediMabBio establishes a bridgehead for the development of immuno-oncology drugs in the UK

MediMabBio has started global clinical trials of its flagship pipeline. After securing R&D funding through a Series A round earlier this year, it will collaborate with a UK clinical trial institution to conduct joint research to develop a treatment for liver cancer.

Ochre Bio Logo

Ochre Bio Raises $9.6M to Advance RNA Therapies for Liver Diseases

The funding will be used to advance the development of Ochre Bio’s RNA therapies and expand its deep phenotyping platform to identify and validate new liver targets.

Introducing OxVax

OXvax Ltd. is a spin-out company from the University of Oxford focused on developing an advanced next-generation dendritic cell vaccine platform for treating solid tumour cancers.

To the left, the OBN Awards logo and the Alchemab Therapeutics logo are on a deep purple background. To the right, there is an image of London overlooking the River Thames. Glitter is falling from the sky.

Alchemab Therapeutics wins Best Start-up Biotech Company at the OBN Awards 2020

Alchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.

BioEscalator Pitch Battle 2021 Flyer

BioEscalator Pitch Battle 2021

PepGen wins the BioEscalator Pitch Battle 2021 with an excellent pitch on how the company is harnessing the power of its Enhanced Delivery Peptide technology to solve the drug-delivery challenge and realize the clinical potential of oligonucleotide therapies to transform the lives of people living with neuromuscular diseases.

Exogene logo

Introducing Exogene

Exogene is a biotechnology company discovering novel T-cell receptor (TCR)-based cell therapies to treat advanced solid tumours.

MoA Technology Graduates from The BioEscalator

MoA Technology graduates from The BioEscalator

MoA Technology is in the process of moving to the Bellhouse Building at the Oxford Science Park to continue its mission to provide farmers with a diverse choice of innovative technologies for weed control.

HRH The Earl of Wessex is pictured on the left. Atherton Mutombwera is pictured on the right. There is an illustration of the city of Oxford skyline below the two images.

HRH The Earl of Wessex visits Oxfordshire virtually

HRH The Earl of Wessex speaks with Oxfordshire entrepreneurs, including Atherton Mutombwera, CEO of Hutano Diagnostics.